Pcn46 - Durable Therapy in Frontline CLL Improves Os

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.128
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

GeDDiS: Insight Into Frontline Therapy in Soft Tissue Sarcoma

The Lancet Oncology
Oncology
2017English

Frontline Therapy in Multiple Myeloma: Fast Start for a Long Game

The Lancet Haematology
Hematology
2019English

Venetoclax: Another Oral Therapy Option for Patients With CLL

Pharmacy Today
2016English

Frontline Therapy for Chronic Lymphocytic Leukemia: The Dilemma Continues

Clinical Cancer Research
Cancer ResearchOncology
2008English

BCL-2 Antagonists: A Proof of Concept for CLL Therapy

Investigational New Drugs
OncologyPharmacology
2013English

CLL

Bone Marrow Transplantation
TransplantationHematology
1999English

Durable Responses After CD19-targeted CAR-T Cell Immunotherapy With Concurrent Ibrutinib for CLL After Prior Ibrutinib Failure

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Clinical Benefit of Antisense Therapy in a Phase III Trial in Patients With CLL

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2007English

Accelerating CAR Therapy in CLL: The Development and Challenges of CAR T Cell Therapy for Chronic Lymphocytic Leukemia

American Journal of Hematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy